FERRING PHARMS INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FERRING PHARMS INC, and what generic alternatives to FERRING PHARMS INC drugs are available?
FERRING PHARMS INC has nine approved drugs.
There are thirteen US patents protecting FERRING PHARMS INC drugs.
There are one hundred and eighty-four patent family members on FERRING PHARMS INC drugs in thirty-nine countries and fifteen supplementary protection certificates in nine countries.
Summary for FERRING PHARMS INC
| International Patents: | 184 |
| US Patents: | 13 |
| Tradenames: | 9 |
| Ingredients: | 4 |
| NDAs: | 9 |
Drugs and US Patents for FERRING PHARMS INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferring Pharms Inc | DDAVP | desmopressin acetate | SOLUTION;NASAL | 017922-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Ferring Pharms Inc | MILPROSA | progesterone | SYSTEM;VAGINAL | 201110-001 | Apr 29, 2020 | DISCN | Yes | No | 8,580,293 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Ferring Pharms Inc | PREPOPIK | citric acid; magnesium oxide; sodium picosulfate | FOR SOLUTION;ORAL | 202535-001 | Jul 16, 2012 | DISCN | Yes | No | 8,481,083 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-001 | Jun 21, 2018 | DISCN | Yes | No | 9,974,826 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Ferring Pharms Inc | MILPROSA | progesterone | SYSTEM;VAGINAL | 201110-001 | Apr 29, 2020 | DISCN | Yes | No | 10,548,904 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Ferring Pharms Inc | DDAVP | desmopressin acetate | INJECTABLE;INJECTION | 018938-001 | Mar 30, 1984 | AP | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FERRING PHARMS INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-002 | Jun 21, 2018 | 10,307,459 | ⤷ Subscribe |
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-001 | Jun 21, 2018 | 9,220,747 | ⤷ Subscribe |
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-002 | Jun 21, 2018 | 8,802,624 | ⤷ Subscribe |
| Ferring Pharms Inc | DDAVP | desmopressin acetate | TABLET;ORAL | 019955-002 | Sep 6, 1995 | 5,674,850 | ⤷ Subscribe |
| Ferring Pharms Inc | CERVIDIL | dinoprostone | INSERT, EXTENDED RELEASE;VAGINAL | 020411-001 | Mar 30, 1995 | 5,269,321 | ⤷ Subscribe |
| Ferring Pharms Inc | DDAVP (NEEDS NO REFRIGERATION) | desmopressin acetate | SPRAY, METERED;NASAL | 017922-003 | Aug 7, 1996 | 5,674,850 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FERRING PHARMS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 10 mg, 3.5 g, and 12 g | ➤ Subscribe | 2014-05-21 |
| ➤ Subscribe | Oral Solution | 10 mg, 3.5 g, and12 g | ➤ Subscribe | 2019-02-11 |
International Patents for FERRING PHARMS INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 110898207 | ⤷ Subscribe |
| Portugal | 3225250 | ⤷ Subscribe |
| Australia | 2003299480 | ⤷ Subscribe |
| Spain | 2596435 | ⤷ Subscribe |
| Japan | 2016153420 | ⤷ Subscribe |
| South Korea | 20050009999 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for FERRING PHARMS INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3225249 | CA 2019 00023 | Denmark | ⤷ Subscribe | PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504 |
| 2861072 | 2024C/512 | Belgium | ⤷ Subscribe | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL, EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (Y COMPRIS SOUS FORME HEMIHYDRATEE) ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406 |
| 2712622 | PA2017001 | Lithuania | ⤷ Subscribe | PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008 |
| 2782584 | 21C1058 | France | ⤷ Subscribe | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406 |
| 2712622 | 122017000006 | Germany | ⤷ Subscribe | PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504 |
| 2782584 | 2021C/558 | Belgium | ⤷ Subscribe | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17--ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
